SNCA-Targeting RNAi Therapeutics Prevent Disease Progression in a Synucleinopathy Mouse Model and Enable Robust, Prolonged, and Safe Alpha-Synuclein Protein Reduction in the Cynomolgus Monkey Central Nervous System
Objective: Assess the nonclinical efficacy and safety of C16-conjugated siRNAs targeting SNCA mRNA (SNCA siRNA). Background: Parkinson’s disease is a neurodegenerative disorder with an estimated…Disease-Modifying Outcomes Following High Intensity Boxing and Sensory Exercise in Parkinson’s Disease: Results From a Double-blinded Randomized Controlled Trial
Objective: The purpose of this study was to determine whether high-intensity exercise (boxing) and sensory exercise (PD SAFEx™) produce disease-modifying effects on motor symptoms following…Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives
Objective: To identify and quantify the age-contingent impact of Friedreich’s Ataxia. Background: Friedreich's ataxia (FA) is a rare, inherited multisystem neurodegenerative disorder that primarily affects…Modeling disease progression in spinocerebellar ataxias
Objective: In the context of emerging gene-targeted therapies for polyglutamine spinocerebellar ataxias (SCAs), identifying predictive clinical markers of disease progression is becoming increasingly relevant. We…Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study
Objective: To evaluate the effect of prasinezumab on delaying disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab is a humanised IgG1…Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease
Objective: To evaluate the long-term safety, tolerability, and PK of the oral, brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease. Background: Preclinical evidence…Clinical Drug-Drug Interaction Profile Of BIA 28-6156: Results From Three Independent Phase I Studies
Objective: Three independent, open-label, clinical drug-drug interaction (DDI) studies were conducted to characterise the clinical DDI profile of BIA 28-6156. Background: BIA 28-6156 (paricerat) is…Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate
Objective: Evaluate efficacy and biomarker response of ATH434 in MSA, including CSF neurofilament light chain (NfL), a prespecified but previously unreported analysis using this disease-severity…A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Multiple System Atrophy
Objective: LYS241, a first-in-class, humanized, and optimized monoclonal antibody, designed to inhibit the interaction between tissue plasminogen activator (tPA) and N-methyl-D-aspartate receptor (NMDAr), has demonstrated…Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s disease: Findings From the PADOVA Phase IIb Study
Objective: To evaluate the effects of prasinezumab on neuroimaging biomarkers in individuals with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: PD is characterized by the…
- 1
- 2
- 3
- …
- 22
- Next Page »